Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753362 · ClinicalTrials.gov registry record · Phase 3
Liraglutide In Overweight Patients With Type 1 Diabetes
A Phase 3 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT01753362 is a Phase 3 study that has completed, run by University at Buffalo. The registered enrollment target is 84 participants.
The verdict
NCT01753362, a Phase 3 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-12 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753362
The ClinicalTrials.gov registry entry for NCT01753362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01753362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01753362 about?
NCT01753362 is a clinical study titled "Liraglutide In Overweight Patients With Type 1 Diabetes". The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.
What is the current status of trial NCT01753362?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2012-12. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01753362?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01753362?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.